Developer docs
API playgroundTry for free, no card

Search company profiles

CanChip

Full company profile

uuid006fmxv

Namestring
CanChip
Legal namestring
CanChip GmbH
Websiteurl
canchip.org
Company typeenum
Private
Founded yearint
2023
Short descriptiontext

CanChip GmbH is a Potsdam-based biotech startup developing tumor-on-a-chip microfluidic platforms that replicate cancer microenvironments for drug testing and personalized oncology, serving pharmaceutical companies, universities, and research institutions through direct enterprise sales and laboratory services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPotsdam, Germany
HQ citystring
Potsdam
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microfluidic chip technology, tumor microenvironment modeling, cancer drug screening, organ-on-chip platforms, preclinical drug testing
Industry1 code
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Microfluidic Cancer Research Platforms
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Chip Platform Sales
TypeHardware Sales
Description

Sale of Tumor-on-a-Chip, Organ-on-a-Chip, and Multi-Organ-on-a-Chip platforms along with microfluidic accessories. Platforms are sold directly to pharmaceutical companies, universities, and research institutions for drug testing and cancer research applications.

canchip.org
2Laboratory Testing Services
TypeProfessional Services
Description

Fee-for-service laboratory testing including drug effectiveness testing, metastasis simulation, genomic profiling, microenvironment interaction studies, drug combination screening, biomarker expression profiling, and long-term culture monitoring.

canchip.org
3Consulting and Technical Support
TypeProfessional Services
Description

Expert consulting services for tumor-on-a-chip research including experimental design, technology integration, troubleshooting, maintenance, data analysis, literature review, grant and manuscript support.

canchip.org
4Training and Workshops
TypeProfessional Services
Description

Customizable training programs and workshops on tumor-on-a-chip technology covering fundamentals, experimental design, and data analysis, targeting researchers, industry professionals, and students.

canchip.org
5Customization Services
TypeOne Time License
Description

Bespoke tumor-on-chip configurations tailored to specific cancer research requirements, including personalized cell types, fluidic conditions, biomarkers, cell lines, and experimental parameters.

canchip.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based pricing for platforms, services, and custom solutions
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is tailored to individual customer needs and project requirements. No public pricing tiers are listed on the company website. Contact-based sales with consultation to determine scope and cost.

canchip.org
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CanChip develops and sells microfluidic tumor-on-a-chip platforms (Tumor-on-a-Chip, Organ-on-a-Chip, Multi-Organ-on-a-Chip, and Bioprinting Chips) that authentically replicate the 3D tumor microenvironment for cancer research, drug screening, and personalized oncology applications. The company also provides microfluidic system accessories, customization services, in-house laboratory testing (drug effectiveness, metastasis simulation, genomic and biomarker profiling), consulting, research support, and training workshops. Customers are pharmaceutical companies, universities, research institutions, and hospitals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Dose-dependent cellular and molecular responses consistent with clinical data in CRC-on-a-Chip studies with 5-FU
+2 more records
Product overview1 text field

CanChip offers a portfolio of microfluidic tumor-on-a-chip products and services for cancer research. The core product line consists of Tumor-on-a-Chip (ToC/CoC) platforms, Organ-on-a-Chip (OoC) systems, Multi-Organ-on-a-Chip (MOoC) platforms, and Bioprinting Chips—all based on cutting-edge microfluidic technology that authentically replicates tumor microenvironments. These platforms are complemented by Customization Services and Microfluidic System Accessories (cell-free chips, porous membranes, chip design). The company also provides an ecosystem of laboratory services including specialized lab facilities (microfluidic, genomics, cell culture), laboratory testing services (drug effectiveness, metastasis simulation, genomic profiling, biomarker expression), and technical/consulting/research support. Training and workshops round out the service offerings. This integrated approach enables pharmaceutical companies and researchers to perform drug testing, personalized medicine studies, and cancer biology research with human-relevant, ethically superior alternatives to traditional methods.

Product and service11 records
1Tumor-on-a-Chip (ToC/CoC)
CategoryMicrofluidic cancer research platform
Description

A microfluidic platform that faithfully recreates realistic 3D tumor microenvironments, including blood vessels and tumor microenvironment components, for drug testing and cancer research. Versatile across various cancer types, it offers a streamlined, cost-effective alternative to traditional 2D cell cultures and animal models and supports studies of tumor growth, metastasis, drug responses, and immune system interactions.

2Organ-on-a-Chip (OoC)
CategoryMicrofluidic organ research platform
Description

An innovative microfluidic system that mimics physiological conditions of human organs, providing a dynamic environment for cellular studies with precision-engineered microfluidic channels recreating organ function complexity. Features real-time monitoring and high-throughput compatibility for drug response and disease mechanism studies.

3Multi-Organ-on-a-Chip (MOoC)
CategoryMicrofluidic multi-organ research platform
Description

A platform integrating multiple organ modules on a single chip to simulate inter-organ communication and human body dynamics, providing a holistic approach to drug testing and disease modeling with precise control over diverse microenvironments.

4Bioprinting Chips
CategoryMicrofluidic cancer research platform
Description

Chips that fuse 3D bioprinting with microfluidic platforms to recreate intricate tumor models on a microscale, replicating structural complexities of tumors and enabling exploration of cell-cell interactions and drug responses with high accuracy.

5Microfluidic System Accessories
CategoryMicrofluidic platform accessories
Description

A curated line of components for microfluidic platforms including cell-free chips (CfC), porous membranes, and chip design services, sold for seamless integration into and customization of CanChip's tumor-on-a-chip platforms.

6Laboratory Testing Services
CategoryLaboratory testing services
Description

Fee-for-service laboratory testing using CanChip's in-house microfluidic, genomics, and cell culture laboratories, including drug effectiveness testing, metastasis simulation, genomic profiling, microenvironment interaction studies, drug combination screening, biomarker expression profiling, and long-term culture monitoring for pharmaceutical and academic customers.

7Consulting Services
CategoryConsulting services
Description

Expert consulting for drug response studies on tumor-on-a-chip platforms, including experimental design optimization, metastasis investigation guidance, and genomic research interpretation for pharmaceutical companies and academic researchers.

8Technical and Lab Support
CategoryTechnical support services
Description

Technical support services covering experimental design and optimization, technology integration assistance, and troubleshooting and maintenance for tumor-on-chip systems used by pharmaceutical and academic customers.

9Research Support Services
CategoryResearch support services
Description

Research assistance including data analysis and interpretation, literature review and trend analysis, and grant and manuscript preparation support for researchers using CanChip's platforms.

10Training and Workshops
CategoryTraining and education services
Description

Customizable training programs and workshops on tumor-on-a-chip technology covering fundamentals, experimental design and optimization, and data analysis and interpretation, targeting researchers, industry professionals, and students.

11Customization Services for Tumor-on-Chip
CategoryCustomization services
Description

Bespoke tumor-on-chip configuration services that tailor CanChip platforms to mimic specific tumor microenvironments, including integration of unique biomarkers, cell lines, fluidic conditions, and experimental parameters for personalized oncology research.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Fraunhofer Institute for Applied Polymer Research (IAP)
Strategic tierCoreTypeTechnology or Integration
Description

CanChip collaborates with Fraunhofer IAP on validating drug absorption in 3D-printed microfluidic devices. Joint external quality report tested device performance using 5-Fluorouracil (5FU) over 72 hours using UV-Vis spectrophotometry. Partnership validates precision and reliability of CanChip's chips for pharmaceutical research applications.

canchip.org
2Fraunhofer Institute for Cell Therapy and Immunology – Branch Bioanalytic and Bioprocesses (IZI-BB)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Located in Potsdam-Golm, Fraunhofer IZI-BB provides state-of-the-art infrastructure for miniaturization and automation of biological processes including biosensor technologies, pipetting robots, and rapid-prototyping. The collaboration supports CanChip's research in biomedicine, diagnostics, and biotechnology applications.

canchip.org
3Dr. Clive Roper
Strategic tierMinorTypeOthers
Description

Dr. Clive Roper, PhD in in vitro dermal metabolism and toxicology from Newcastle University, provides expert consulting in optimal marketing and commercialization of tumor-on-chip technology. He is board chairperson of PeptiMatrix, board member of 3Rs Collaborative and NC3Rs, and Vice President of ESTIV, supporting regulatory acceptance and NAM (New Approach Methodologies) adoption.

canchip.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

CanChip CEO Ghazaleh Madani conducted her master's thesis research at Preclinic GmbH from May 2022 to February 2023, working on a research and development project with an immunization and antibody production base. Indicates prior collaborative research relationship.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CanChip actively collaborates with universities for joint research projects, student theses (PhD and Master's), and postdoc projects in cancer biology and tumor-on-chip applications. The company cooperates with scientific and research centers, and professors to advance personalized medicine in cancer biology. Co-development of chip models and shared publication of research findings.

6Pharmaceutical Companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CanChip works with pharmaceutical companies for drug screening, preclinical testing, and development of personalized treatment strategies. Partnerships aimed at enabling pharma companies to evaluate drug efficacy and safety using patient-relevant tumor-on-chip models, reducing animal testing and development costs.

canchip.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Emulate is the leading commercial organ-on-chip platform (Human Emulation System) used across pharma R&D and academia for liver, lung, gut, and brain models. It directly overlaps with CanChip's OoC/MOoC technology category and serves the same pharma buyer, but operates at vastly larger scale across multiple organ indications versus CanChip's oncology focus.

TypeDirect peer
Description

TissUse is a Berlin-based organ-on-chip company specializing in multi-organ-chip (MOC) systems for ADMET profiling and systemic toxicity testing. Its multi-organ focus and DACH location make it a particularly close regional peer to CanChip's MOoC platform.

3Kirkstall
TypeEmerging player
Description

Kirkstall is a UK-based organ-on-chip company offering the Quasi Vivo connected cell culture system for multi-organ and toxicology applications. It overlaps with CanChip's MOoC positioning around inter-organ communication.

TypeEmerging player
Description

SynVivo develops microfluidic tumor-on-a-chip and organ-on-chip platforms that mimic in vivo microenvironments for cancer drug screening and inflammation studies. It is a close technology peer to CanChip in the tumor-on-chip niche specifically.

5Nortis Bio
TypeEmerging player
Description

Nortis Bio (formerly Nortis) provides microfluidic organ-on-chip systems for kidney, vascular, and cancer applications. Its tumor-vascular and angiogenesis-on-chip work directly parallels CanChip's CRC-on-a-Chip approach.

6CN Bio
TypeDirect peer
Description

CN Bio offers the PhysioMimix organ-on-chip platform for single- and multi-organ microphysiological systems used in drug discovery and disease modeling. It is a direct competitor to CanChip in the OoC/MOoC category, with established pharma partnerships and a similar go-to-market targeting preclinical researchers.

TypeDirect peer
Description

InSphero provides 3D microtissue and organoid-based disease models for drug discovery and toxicology. While not strictly microfluidic, its 3D cell culture and oncology applications overlap with CanChip's tumor-on-a-chip offering for pharma and academic buyers.

8Hurel Corporation
TypeEmerging player
Description

Hurel develops microfluidic liver-on-chip and other tissue-on-chip platforms for ADMET and toxicology testing used by pharma companies. It is a comparable microfluidic preclinical platform vendor, although with different primary organ focus than CanChip.

TypeDirect peer
Description

MIMETAS develops the OrganoPlate organ-on-chip platform for high-throughput 3D cell culture and disease modeling, including oncology-relevant models. It competes head-to-head with CanChip's OoC and Bioprinting Chips in academic and pharma research channels.

10CellFE.ai
TypeOthers
Description

CellFE.ai uses microfluidic-based cell engineering for cell therapy and gene therapy manufacturing. While not a tumor-on-chip competitor, it sits in the same microfluidic biotech infrastructure ecosystem serving next-generation cell-based therapies and is adjacent to CanChip's technology stack.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CanChip

Microfluidic Cancer Research Platformscanchip.org

CanChip GmbH is a Potsdam-based biotech startup developing tumor-on-a-chip microfluidic platforms that replicate cancer microenvironments for drug testing and personalized oncology, serving pharmaceutical companies, universities, and research institutions through direct enterprise sales and laboratory services.

CanChip firmographics

Firmographics
Name
CanChip
Legal name
CanChip GmbH
Website
https://canchip.org
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
CanChip GmbH is a Potsdam-based biotech startup developing tumor-on-a-chip microfluidic platforms that replicate cancer microenvironments for drug testing and personalized oncology, serving pharmaceutical companies, universities, and research institutions through direct enterprise sales and laboratory services.
Ownership category
akta.pro rank

CanChip industry classification

Industry
Product category
Microfluidic Cancer Research Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Microfluidic chip technology
  • Tumor microenvironment modeling
  • Cancer drug screening
  • Organ-on-chip platforms
  • Preclinical drug testing

Where CanChip is headquartered

Location

Headquarters

HQ city
Potsdam
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

CanChip business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Chip Platform Sales: Sale of Tumor-on-a-Chip, Organ-on-a-Chip, and Multi-Organ-on-a-Chip platforms along with microfluidic accessories. Platforms are sold directly to pharmaceutical companies, universities, and research institutions for drug testing and cancer research applications.
  2. Laboratory Testing Services: Fee-for-service laboratory testing including drug effectiveness testing, metastasis simulation, genomic profiling, microenvironment interaction studies, drug combination screening, biomarker expression profiling, and long-term culture monitoring.
  3. Consulting and Technical Support: Expert consulting services for tumor-on-a-chip research including experimental design, technology integration, troubleshooting, maintenance, data analysis, literature review, grant and manuscript support.
  4. Training and Workshops: Customizable training programs and workshops on tumor-on-a-chip technology covering fundamentals, experimental design, and data analysis, targeting researchers, industry professionals, and students.
  5. Customization Services: Bespoke tumor-on-chip configurations tailored to specific cancer research requirements, including personalized cell types, fluidic conditions, biomarkers, cell lines, and experimental parameters.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based pricing for platforms, services, and custom solutions

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

CanChip product offering

Product offering

Core offering

CanChip develops and sells microfluidic tumor-on-a-chip platforms (Tumor-on-a-Chip, Organ-on-a-Chip, Multi-Organ-on-a-Chip, and Bioprinting Chips) that authentically replicate the 3D tumor microenvironment for cancer research, drug screening, and personalized oncology applications. The company also provides microfluidic system accessories, customization services, in-house laboratory testing (drug effectiveness, metastasis simulation, genomic and biomarker profiling), consulting, research support, and training workshops. Customers are pharmaceutical companies, universities, research institutions, and hospitals.

Product overview

CanChip offers a portfolio of microfluidic tumor-on-a-chip products and services for cancer research. The core product line consists of Tumor-on-a-Chip (ToC/CoC) platforms, Organ-on-a-Chip (OoC) systems, Multi-Organ-on-a-Chip (MOoC) platforms, and Bioprinting Chips—all based on cutting-edge microfluidic technology that authentically replicates tumor microenvironments. These platforms are complemented by Customization Services and Microfluidic System Accessories (cell-free chips, porous membranes, chip design). The company also provides an ecosystem of laboratory services including specialized lab facilities (microfluidic, genomics, cell culture), laboratory testing services (drug effectiveness, metastasis simulation, genomic profiling, biomarker expression), and technical/consulting/research support. Training and workshops round out the service offerings. This integrated approach enables pharmaceutical companies and researchers to perform drug testing, personalized medicine studies, and cancer biology research with human-relevant, ethically superior alternatives to traditional methods.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tumor-on-a-Chip (ToC/CoC) A microfluidic platform that faithfully recreates realistic 3D tumor microenvironments, including blood vessels and tumor microenvironment components, for drug testing and cancer research. Versatile across various cancer types, it offers a streamlined, cost-effective alternative to traditional 2D cell cultures and animal models and supports studies of tumor growth, metastasis, drug responses, and immune system interactions.
  • Organ-on-a-Chip (OoC) An innovative microfluidic system that mimics physiological conditions of human organs, providing a dynamic environment for cellular studies with precision-engineered microfluidic channels recreating organ function complexity. Features real-time monitoring and high-throughput compatibility for drug response and disease mechanism studies.
  • Multi-Organ-on-a-Chip (MOoC) A platform integrating multiple organ modules on a single chip to simulate inter-organ communication and human body dynamics, providing a holistic approach to drug testing and disease modeling with precise control over diverse microenvironments.
  • Bioprinting Chips Chips that fuse 3D bioprinting with microfluidic platforms to recreate intricate tumor models on a microscale, replicating structural complexities of tumors and enabling exploration of cell-cell interactions and drug responses with high accuracy.
  • Microfluidic System Accessories A curated line of components for microfluidic platforms including cell-free chips (CfC), porous membranes, and chip design services, sold for seamless integration into and customization of CanChip's tumor-on-a-chip platforms.
  • Laboratory Testing Services Fee-for-service laboratory testing using CanChip's in-house microfluidic, genomics, and cell culture laboratories, including drug effectiveness testing, metastasis simulation, genomic profiling, microenvironment interaction studies, drug combination screening, biomarker expression profiling, and long-term culture monitoring for pharmaceutical and academic customers.
  • Consulting Services Expert consulting for drug response studies on tumor-on-a-chip platforms, including experimental design optimization, metastasis investigation guidance, and genomic research interpretation for pharmaceutical companies and academic researchers.
  • Technical and Lab Support Technical support services covering experimental design and optimization, technology integration assistance, and troubleshooting and maintenance for tumor-on-chip systems used by pharmaceutical and academic customers.
  • Research Support Services Research assistance including data analysis and interpretation, literature review and trend analysis, and grant and manuscript preparation support for researchers using CanChip's platforms.
  • Training and Workshops Customizable training programs and workshops on tumor-on-a-chip technology covering fundamentals, experimental design and optimization, and data analysis and interpretation, targeting researchers, industry professionals, and students.
  • Customization Services for Tumor-on-Chip Bespoke tumor-on-chip configuration services that tailor CanChip platforms to mimic specific tumor microenvironments, including integration of unique biomarkers, cell lines, fluidic conditions, and experimental parameters for personalized oncology research.

Quantifiable outcome

  • Dose-dependent cellular and molecular responses consistent with clinical data in CRC-on-a-Chip studies with 5-FU
  • +2 more outcomes

Companies that use CanChip

Customer profile

Segments3 records

Ideal customer profiles3 records

CanChip technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

CanChip partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Fraunhofer Institute for Applied Polymer Research (IAP)coreTechnology or IntegrationCanChip collaborates with Fraunhofer IAP on validating drug absorption in 3D-printed microfluidic devices. Joint external quality report tested device performance using 5-Fluorouracil (5FU) over 72 hours using UV-Vis spectrophotometry. Partnership validates precision and reliability of CanChip's chips for pharmaceutical research applications.
  • Fraunhofer Institute for Cell Therapy and Immunology – Branch Bioanalytic and Bioprocesses (IZI-BB)coreStrategic or Co-development PartnerLocated in Potsdam-Golm, Fraunhofer IZI-BB provides state-of-the-art infrastructure for miniaturization and automation of biological processes including biosensor technologies, pipetting robots, and rapid-prototyping. The collaboration supports CanChip's research in biomedicine, diagnostics, and biotechnology applications.
  • Dr. Clive RoperminorOthersDr. Clive Roper, PhD in in vitro dermal metabolism and toxicology from Newcastle University, provides expert consulting in optimal marketing and commercialization of tumor-on-chip technology. He is board chairperson of PeptiMatrix, board member of 3Rs Collaborative and NC3Rs, and Vice President of ESTIV, supporting regulatory acceptance and NAM (New Approach Methodologies) adoption.
  • Preclinic GmbHminorStrategic or Co-development PartnerCanChip CEO Ghazaleh Madani conducted her master's thesis research at Preclinic GmbH from May 2022 to February 2023, working on a research and development project with an immunization and antibody production base. Indicates prior collaborative research relationship.
  • Universities and Research InstitutionscoreStrategic or Co-development PartnerCanChip actively collaborates with universities for joint research projects, student theses (PhD and Master's), and postdoc projects in cancer biology and tumor-on-chip applications. The company cooperates with scientific and research centers, and professors to advance personalized medicine in cancer biology. Co-development of chip models and shared publication of research findings.
  • Pharmaceutical CompaniescoreStrategic or Co-development PartnerCanChip works with pharmaceutical companies for drug screening, preclinical testing, and development of personalized treatment strategies. Partnerships aimed at enabling pharma companies to evaluate drug efficacy and safety using patient-relevant tumor-on-chip models, reducing animal testing and development costs.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

CanChip competitors and assessment

Company assessment

Broad incumbents

  • Emulate: Emulate is the leading commercial organ-on-chip platform (Human Emulation System) used across pharma R&D and academia for liver, lung, gut, and brain models. It directly overlaps with CanChip's OoC/MOoC technology category and serves the same pharma buyer, but operates at vastly larger scale across multiple organ indications versus CanChip's oncology focus.

Direct peers

  • TissUse: TissUse is a Berlin-based organ-on-chip company specializing in multi-organ-chip (MOC) systems for ADMET profiling and systemic toxicity testing. Its multi-organ focus and DACH location make it a particularly close regional peer to CanChip's MOoC platform.
  • CN Bio: CN Bio offers the PhysioMimix organ-on-chip platform for single- and multi-organ microphysiological systems used in drug discovery and disease modeling. It is a direct competitor to CanChip in the OoC/MOoC category, with established pharma partnerships and a similar go-to-market targeting preclinical researchers.
  • InSphero: InSphero provides 3D microtissue and organoid-based disease models for drug discovery and toxicology. While not strictly microfluidic, its 3D cell culture and oncology applications overlap with CanChip's tumor-on-a-chip offering for pharma and academic buyers.
  • MIMETAS: MIMETAS develops the OrganoPlate organ-on-chip platform for high-throughput 3D cell culture and disease modeling, including oncology-relevant models. It competes head-to-head with CanChip's OoC and Bioprinting Chips in academic and pharma research channels.

Emerging players

  • Kirkstall: Kirkstall is a UK-based organ-on-chip company offering the Quasi Vivo connected cell culture system for multi-organ and toxicology applications. It overlaps with CanChip's MOoC positioning around inter-organ communication.
  • SynVivo: SynVivo develops microfluidic tumor-on-a-chip and organ-on-chip platforms that mimic in vivo microenvironments for cancer drug screening and inflammation studies. It is a close technology peer to CanChip in the tumor-on-chip niche specifically.
  • Nortis Bio: Nortis Bio (formerly Nortis) provides microfluidic organ-on-chip systems for kidney, vascular, and cancer applications. Its tumor-vascular and angiogenesis-on-chip work directly parallels CanChip's CRC-on-a-Chip approach.
  • Hurel Corporation: Hurel develops microfluidic liver-on-chip and other tissue-on-chip platforms for ADMET and toxicology testing used by pharma companies. It is a comparable microfluidic preclinical platform vendor, although with different primary organ focus than CanChip.

Others

  • CellFE.ai: CellFE.ai uses microfluidic-based cell engineering for cell therapy and gene therapy manufacturing. While not a tumor-on-chip competitor, it sits in the same microfluidic biotech infrastructure ecosystem serving next-generation cell-based therapies and is adjacent to CanChip's technology stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CanChip social profiles

Digital presence

CanChip financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CanChip leadership team

Management profile

Number of profiles

Profiles3 records

CanChip funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CanChip M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanChip

What does CanChip do?

CanChip develops and sells microfluidic tumor-on-a-chip platforms (Tumor-on-a-Chip, Organ-on-a-Chip, Multi-Organ-on-a-Chip, and Bioprinting Chips) that authentically replicate the 3D tumor microenvironment for cancer research, drug screening, and personalized oncology applications. The company also provides microfluidic system accessories, customization services, in-house laboratory testing (drug effectiveness, metastasis simulation, genomic and biomarker profiling), consulting, research support, and training workshops. Customers are pharmaceutical companies, universities, research institutions, and hospitals.

Is CanChip a public or private company?

CanChip is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CanChip founded?

CanChip was founded in 2023. It employs 1 to 10 people.

Where is CanChip based?

CanChip is headquartered in Potsdam, Germany, in the Europe region.

How does CanChip make money?

Five revenue lines are on record. Chip Platform Sales are the primary driver. The others are laboratory Testing Services, consulting and Technical Support, training and Workshops and customization Services.

Who are CanChip's main competitors?

Emulate is listed as a broad incumbent. Direct peers are TissUse, CN Bio, InSphero and MIMETAS. Emerging players are Kirkstall, SynVivo, Nortis Bio and Hurel Corporation. CellFE.ai is listed as an others.

Does CanChip have an API?

No public API is recorded for CanChip.

What industry is CanChip in?

CanChip's product category is Microfluidic Cancer Research Platforms. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals